{
    "id": 13306,
    "fullName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY",
    "impact": "insertion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 Y599_D600insSTDNEYFYVDFREYEY results in the insertion of sixteen amino acids in the juxtamembrane domain of the Flt3 protein between amino acids 599 and 600 (UniProt.org). Y599_D600insSTDNEYFYVDFREYEY has not been biochemically characterized, but can be predicted to lead to activation of Flt3 based on the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077).",
            "references": [
                {
                    "id": 2898,
                    "pubMedId": 11090077,
                    "title": "Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/11090077"
                },
                {
                    "id": 2896,
                    "pubMedId": 12970773,
                    "title": "FLT3: ITDoes matter in leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12970773"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 2897,
                    "pubMedId": 9737679,
                    "title": "Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9737679"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "Y599_D600insSTDNEYFYVDFREYEY",
    "createDate": "10/28/2015",
    "updateDate": "10/05/2018",
    "referenceTranscriptCoordinates": {
        "id": 144628,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28034124_28034125insCTCATACTCCCTAAAGTCTACATAAAAATACTCGTTGTCTGTGCTATA",
        "cDna": "c.1797_1798insAGCACAGACAACGAGTATTTTTATGTAGACTTTAGGGAGTATGAGTAT",
        "protein": "p.Y599_D600insSTDNEYFYVDFREYEY",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3596,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I clinical trial, patients with refractory or relapsed acute myeloid leukemia positive for FLT3-ITD demonstrated a 53% (9/17) response rate compared to a 14% (5/37) response rate in those patients negative for FLT3-ITD when treated with Quizartinib (AC220) (PMID: 24002496).",
            "molecularProfile": {
                "id": 13493,
                "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3874,
                    "pubMedId": 24002496,
                    "title": "Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24002496"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3578,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, 93% (40/43) of acute myeloid leukemia patients harbored a FLT3-ITD and of the 37 patients that were evaluable, the combination therapy, Nexavar (sorafenib) and Vidaza (azacitidine), resulted in a 46% (17/37) response rate, which included 10 CRi, 6 CR, and 1 PR (PMID: 23613521).",
            "molecularProfile": {
                "id": 13493,
                "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY"
            },
            "therapy": {
                "id": 1633,
                "therapyName": "Azacitidine + Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3852,
                    "pubMedId": 23613521,
                    "title": "Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23613521"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 3590,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3-ITD secondary resistance mutation demonstrated sensitivity to FLX925 (Cancer Res, August 1, 2015 75; 787).",
            "molecularProfile": {
                "id": 13493,
                "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY"
            },
            "therapy": {
                "id": 2529,
                "therapyName": "FLX925",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3864,
                    "pubMedId": null,
                    "title": "Abstract 787: FLX925 (AMG 925) is a rationally designed FLT3, CDK4/6 inhibitor that retains potency against clinically relevant secondary resistance mutations in FLT3",
                    "url": "http://cancerres.aacrjournals.org/content/75/15_Supplement/787.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3588,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, E6201 induced cell death, inhibited cell growth, and decreased tumor burden in acute myeloid leukemia cells harboring FLT3-ITD mutations in culture and in cell line xenograft models (Blood Nov 2013, 122 (21) 2683).",
            "molecularProfile": {
                "id": 13493,
                "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY"
            },
            "therapy": {
                "id": 1011,
                "therapyName": "E6201",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3838,
                    "pubMedId": null,
                    "title": "Study Of Activity Of E6201, a Dual FLT3 and MEK Inhibitor, In Acute Myelogenous Leukemia With FLT3 Or RAS Mutation",
                    "url": "http://www.bloodjournal.org/content/122/21/2683?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3593,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Enasidenib (AG-221) and Quizartinib (AC220) stimulated leukemic cell differentiation and reduced leukemic cell self-renewal in an acute myeloid leukemia mouse model simultaneously expressing IDH2 R140Q and a FLT3-ITD mutation (Blood Dec 2014, 124 (21) 437).",
            "molecularProfile": {
                "id": 13759,
                "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY IDH2 R140W"
            },
            "therapy": {
                "id": 3172,
                "therapyName": "Enasidenib + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3871,
                    "pubMedId": null,
                    "title": "AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo",
                    "url": "http://www.bloodjournal.org/content/124/21/437?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 13493,
            "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY",
            "profileTreatmentApproaches": [
                {
                    "id": 6995,
                    "name": "FLT3 Inhibitor",
                    "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY"
                }
            ]
        },
        {
            "id": 13674,
            "profileName": "DNMT3A R882H FLT3 Y599_D600insSTDNEYFYVDFREYEY NPM1 W288fs",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 13759,
            "profileName": "FLT3 Y599_D600insSTDNEYFYVDFREYEY IDH2 R140W",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144628,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28034124_28034125insCTCATACTCCCTAAAGTCTACATAAAAATACTCGTTGTCTGTGCTATA",
            "cDna": "c.1797_1798insAGCACAGACAACGAGTATTTTTATGTAGACTTTAGGGAGTATGAGTAT",
            "protein": "p.Y599_D600insSTDNEYFYVDFREYEY",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}